Last reviewed · How we verify

CMAB807 Injection — Competitive Intelligence Brief

CMAB807 Injection (CMAB807 Injection) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Area: Oncology.

phase 3 Oncology Small molecule Live · refreshed every 30 min

Target snapshot

CMAB807 Injection (CMAB807 Injection) — Shanghai Biomabs Pharmaceutical Co., Ltd.. CMAB807 is a monoclonal antibody that targets and inhibits a specific immune checkpoint or tumor-associated antigen to enhance anti-tumor immunity or reduce pathological immune responses.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
CMAB807 Injection TARGET CMAB807 Injection Shanghai Biomabs Pharmaceutical Co., Ltd. phase 3

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape

No sponsor landscape data.

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). CMAB807 Injection — Competitive Intelligence Brief. https://druglandscape.com/ci/cmab807-injection. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators: